MethylGene Inc - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 105

MethylGene Inc – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “MethylGene Inc - Product Pipeline Review - H2 2011” provides data on the MethylGene Inc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, MethylGene Inc’s corporate website, SEC filings, investor presentations and featured press releases, both from MethylGene Inc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- MethylGene Inc - Brief MethylGene Inc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MethylGene Inc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MethylGene Inc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MethylGene Inc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MethylGene Inc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MethylGene Inc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MethylGene Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MethylGene Inc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MethylGene Inc and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of MethylGene Inc; MethylGene Inc - Key Therapeutics; MethylGene Inc - Pipeline Overview and Promising Molecules; MethylGene Inc - News; MethylGene Inc - Latest Updates; MethylGene Inc - Pipeline; MethylGene Inc - Discontinued/Dormant Projects

List of Tables
List of Figures
MethylGene Inc Snapshot
MethylGene Inc Overview
Key Information
Key Facts
MethylGene Inc – Research and Development Overview
Key Therapeutic Areas
MethylGene Inc – Pipeline Review
Pipeline Products by Stage of Development
MethylGene Inc – Pipeline Products Glance
MethylGene Inc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
MethylGene Inc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
MethylGene Inc – Drug Profiles
Kinase Inhibitors Program
Product Description
Mechanism of Action
R&D Progress
MG516
Product Description
Mechanism of Action
R&D Progress
MG91516
Product Description
Mechanism of Action
R&D Progress
MG96077
Product Description
Mechanism of Action
R&D Progress
MGCD0103 + Gemzar
Product Description
Mechanism of Action
R&D Progress
MGCD265
Product Description
Mechanism of Action
R&D Progress
MGCD265 + Docetaxel
Product Description
Mechanism of Action
R&D Progress
MGCD265 + Erlotinib
Product Description
Mechanism of Action
R&D Progress
MGCD290
Product Description
Mechanism of Action
R&D Progress
MGCD290 + Fluconazole
Product Description
Mechanism of Action
R&D Progress
Mocetinostat
Product Description
Mechanism of Action
R&D Progress
Sirtuin Inhibitor Program
Product Description
Mechanism of Action
R&D Progress
MethylGene Inc – Pipeline Analysis
MethylGene Inc – Pipeline Products by Therapeutic Class
MethylGene Inc - Pipeline Products By Target
MethylGene Inc – Pipeline Products by Route of Administration
MethylGene Inc – Pipeline Products by Molecule Type
MethylGene Inc – Recent Pipeline Updates
MethylGene Inc - Dormant Projects
MethylGene Inc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
MG98
MG98 + Interferon
MGCD0103 + Taxotere
MGCD0103 + Vidaza
MethylGene Inc – Company Statement
MethylGene Inc – Locations And Subsidiaries
Head Office
Recent Developments
Nov 29, 2010: Methylgene To Present Final Phase II Clinical Data Of Mocetinostat At ASH Annual Meeting
Sep 29, 2006: Methylgene Reports Preclinical Results Of Its Antifungal Compound MG3290 In Combination With Azoles
Mar 29, 2011: MethylGene To Present MGCD265 Data At American Association for Cancer Research Annual Meeting
Mar 29, 2004: Further Preclinical Evidence Of Synergy and Molecular Activity Of MG98, A Novel Anticancer Compound, Disclosed At 2004 AACR
Sep 28, 2010: Methylgene Wins Two US Patents For MGCD265
May 28, 2009: MethylGene Reports Favorable Preliminary Phase I Data For MGCD265, Its Multi-Targeted (c-Met) Kinase Inhibitor.
Oct 27, 2008: MethylGene Reacquires Rights To MGCD0103 From Celgene And Implements Strategic Plan To Focus On Development Of Proprietary Clinical Pipeline
Jun 25, 2008: Methylgene Initiates Phase II Trial Of MGCD0103 In Combination With Vidaza In Patients With High-Risk MDS or AML
Jun 24, 2003: MethylGene Signs Worldwide Agreement With Merck-Frosst Canada & Co. On Antibiotic And Antibiotic Resistance Program
May 24, 2007: MethylGene Presents Preclinical Data For Its Clinical Candidate MGCD290, An Antifungal Histone Deacetylase Inhibitor
Jul 22, 2008: MethylGene and Celgene Corporation Announce Precautionary Suspension Of New Enrollments Into MGCD0103 Clinical Trials
Sep 21, 2009: MethylGene To Resume Development Of Its HDAC Inhibitor, MGCD0103 (Mocetinostat)
Apr 21, 2009: MethylGene Presents Preclinical Data For Its Second Generation Oral Kinase Inhibitor, MG516
Dec 20, 2004: MethylGene Initiates Phase I HDAC Cancer Trial In Hematological Malignancies MGCD0103 To Be Tested In Leukemias And Myelodysplastic Syndrome
Oct 20, 2003: delete/ MethylGene Announces Oncology Collaboration Worth US$37.5 Million
Aug 20, 2007: Methylgene And Pharmion Announce Collaboration To Develop Sirtuin Inhibitors As Anti-Cancer Agents
Apr 20, 2010: Methylgene Presents Preclinical Data For MGCD265 At AACR Annual Meeting
Sep 19, 2008: MethylGene Exercises Right To Convert MGCD0103 Collaboration With Celgene To Pre-Determined Royalty And Milestone Arrangement
Sep 19, 2007: Methylgene Presents Preclinical Data For Its Clinical Candidate MGCD290, An Antifungal Histone Deacetylase Inhibitor
Nov 18, 2010: Methylgene Presents Encouraging Clinical Data From CD265 In Solid Tumor Cancers At 22nd EORTC-NCI-AACR Annual Meeting
Nov 18, 2010: Methylgene Presents Encouraging Clinical Data On CD265 With Erlotinib In Solid Tumor Cancers At EORTC-NCI-AACR Annual Meeting
Oct 18, 2011: MethylGene Receives FDA IND Approval To Begin Phase II Clinical Trial With MGCD290
May 17, 2007: Methylgene Selects Histone Deacetylase Antifungal Clinical Candidate
May 16, 2005: Methylgene Discloses Preliminary MGCD0103 (An ORAL HDAC Inhibitor) Phase I Clinical Data At ASCO
Apr 16, 2008: MethylGene Presents Preclinical Data For Its Multi-Targeted (c-Met) Kinase Inhibitor, MGCD265, At American Association For Cancer Research Annual Meeting
Oct 15, 2008: MethylGene Initiates Phase I Clinical Study With MGCD290 For Fungal Infections.
Sep 15, 2009: MethylGene Presents Phase I Data For Its Novel Antifungal Agent, MGCD290, At The 49th Annual ICAAC Meeting
Dec 14, 2006: MethylGene Will Not Pursue Additional Cinical Trials For MG98
Nov 14, 2005: Methylgene Initiates Phase I/II Clinical Trial With MGCD0103 And Azacitidine In Patients With MDS And AML
Sep 14, 2009: MethylGene Presents Preclinical Data For Its Beta-Lactamase Inhibitor, MG96077
Jun 14, 2011: MethylGene Provides Clinical Update Of Hos2 Inhibitor MGCD290 For Fungal Infections
Jun 14, 2011: MethylGene Provides Clinical Update On Met / VEGF Inhibitor MGCD265 For Cancer
Sep 13, 2010: Methylgene Presents Phase I Data Of MGCD290 At 50th Annual ICAAC Meeting
Sep 13, 2010: Methylgene Presents Phase I Data Of MGCD290 In Combination With Fluconazole At 50th Annual ICAAC Meeting
Jun 12, 2008: MethylGene Initiates Second Phase I Clinical Trial With MGCD265, A Multi-Targeted (c-Met) Kinase Inhibitor In Patients With Solid Tumors
Dec 11, 2006: Methylgene Reports Positve Data in Ash Annual Meeting For MGCD0103, An Oral, Isotype-Selective HDAC Inhibitor
Dec 10, 2007: Methylgene And Pharmion Present Favorable Clinical Data From Combination MGCD0103/Vidaza Study In MS And AML
Jun 07, 2010: Methylgene Presents Encouraging Clinical Data Of MGCD265 At ASCO 2010 Annual Meeting
Jun 07, 2010: Methylgene Presents Encouraging Preclinical Data For MGCD265 At ASCO 2010 Annual Meeting
Jun 07, 2010: Methylgene Presents Phase II Clinical Data For Mocetinostat At ASCO 2010 Annual Meeting
Dec 06, 2010: Methylgene Reports Favorable Final Phase II Clinical Data Of Mocetinostat In Hodgkin Lymphoma
Jan 04, 2008: MethylGene Files IND For MGCD265, Multi-Targeted Kinase (C-MET) Inhibitor For Oncology.
Jun 03, 2008: MethylGene Reports Clinical Data From A Phase II Study Evaluating MGCD0103 In Relapsed Or Refractory Non-Hodgkin Lymphomas
Oct 02, 2008: Methylgene Receives Clinical Trial Approval From Health Canada For Its Proprietary Product Candidate MGCD290 For Fungal Infections
Sep 02, 2009: MethylGene Initiates Phase II Program For MGCD265 In Solid Tumors And Non-Small Cell Lung Cancer Patients
Aug 01, 2007: MethylGene Regains Exclusive Rights To Beta-Lactamase Inhibitor Program From Merck
Jun 01, 2008: Pharmion And MethylGene Announce The Enrollment Of The First Patient In a Phase II clinical trial (Trial CL002) Evaluating MGCD0103 In Combination With Vidaza
Mar 01, 2002: MGI Pharma/Methylgene Begin Clinical Trial Of MG98
Financial Deals Landscape
MethylGene Inc, Deals Summary
MethylGene Inc, Pharmaceuticals & Healthcare, Deal Details
Partnerships
MethylGene Extends Its Research Collaboration With Otsuka Pharmaceutical
MethylGene Enters Into Royalty Stream And Milestone Arrangement With Celgene
Methylgene Enters Into Research Agreement With Pharmion
MethylGene And EnVivo Enter Into A Co-Development Agreement With CHDI
Licensing Agreements
Otsuka Pharmaceutical Extends Its Licensing Agreement With MethylGene
Methylgene Enters Into Collaboration And Licensing Agreement With Otsuka
MethylGene Enters Into License And Collaboration Agreement With Pharmion
MethylGene Enters Into Licensing Agreement With EnVivo Pharmaceuticals For Neurodegenerative Disorders
MethylGene Enters Into Licensing Agreement With EnVivo Pharmaceuticals
Equity Offering
MethylGene Completes Private Placement Of $35.15 Million
MethylGene Announces Private Placement Of $15 Million
MethylGene Completes Private Placement Of $9.1 Million
MethylGene Completes Bought Deal Offering Of $17 Million
MethylGene Completes Private Placement Of $19 Million
MethylGene Completes Initial Public Offering Of $19 Million
MethylGene Completes Private Placement Of $1 Million
Debt Offering
MethylGene Completes Private Placement Of Senior Unsecured Debentures For $0.39 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
MethylGene Inc – Pipeline by Therapy Area and Indication, H2 2011
MethylGene Inc – Pipeline by Stage of Development, H2 2011
MethylGene Inc - Phase II, H2 2011
MethylGene Inc - Phase I, H2 2011
MethylGene Inc - Pipeline By Therapeutic Class, H2 2011
MethylGene Inc - Pipeline By Target, H2 2011
MethylGene Inc – Pipeline By Route of Administration, H2 2011
MethylGene Inc – Pipeline By Molecule Type, H2 2011
MethylGene Inc – Recent Pipeline Updates, H2 2011
MethylGene Inc - Dormant Developmental Projects, 2010
MethylGene Inc - Discontinued Pipeline Products, 2010
MethylGene Inc, Deals Summary
MethylGene Extends Its Research Collaboration With Otsuka Pharmaceutical
MethylGene Enters Into Royalty Stream And Milestone Arrangement With Celgene
Methylgene Enters Into Research Agreement With Pharmion
MethylGene And EnVivo Enter Into A Co-Development Agreement With CHDI
Otsuka Pharmaceutical Extends Its Licensing Agreement With MethylGene
Methylgene Enters Into Collaboration And Licensing Agreement With Otsuka
MethylGene Enters Into License And Collaboration Agreement With Pharmion
MethylGene Enters Into Licensing Agreement With EnVivo Pharmaceuticals For Neurodegenerative Disorders
MethylGene Enters Into Licensing Agreement With EnVivo Pharmaceuticals
MethylGene Completes Private Placement Of $35.15 Million
MethylGene Announces Private Placement Of $15 Million
MethylGene Completes Private Placement Of $9.1 Million
MethylGene Completes Bought Deal Offering Of $17 Million
MethylGene Completes Private Placement Of $19 Million
MethylGene Completes Initial Public Offering Of $19 Million
MethylGene Completes Private Placement Of $1 Million
MethylGene Completes Private Placement Of Senior Unsecured Debentures For $0.39 Million

List of Figures
MethylGene Inc – Pipeline by Therapy Area and Indication, H2 2011
MethylGene Inc – Pipeline by Stage of Development, H2 2011
MethylGene Inc – Pipeline By Therapeutic Class, H2 2011
MethylGene Inc - Pipeline By Target, H2 2011
MethylGene Inc – Pipeline By Route of Administration, H2 2011
MethylGene Inc – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile